Novanta, a provider of precision medicine and advanced technology solutions, announced that it has entered into a securities purchase agreement for a private placement expected to generate approximately $300 million in gross proceeds before fees and expenses.
Under the terms of the agreement, institutional and other accredited investors agreed to purchase an aggregate of 2,142,857 common shares at a price of $140 per share. The transaction is expected to close on or around June 11, 2026, subject to customary closing conditions.
The proceeds from the financing will provide additional capital to support the company’s strategic initiatives. Concurrent with the execution of the securities purchase agreement, Novanta entered into a registration rights agreement with investors, under which the company agreed to register the resale of the shares issued in the private placement.
The transaction was structured as a private offering and the common shares have not been registered under the Securities Act of 1933. Accordingly, the shares may not be offered or resold in the United States without an effective registration statement or an applicable exemption from registration requirements.
Novanta noted that the transaction is expected to provide approximately $300 million in gross proceeds and remains subject to customary closing conditions.
